RA0490

antibody from Oursmab

Targeting: MMP9 CLG4B

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0490

Provider

Oursmab

Product name

Andecaliximab (Biosimilar Reference Antibody) (MMP9)

Antibody type

Monoclonal

Description

Andecaliximab is a humanized IgG4 monoclonal antibody designed as a specific inhibitor of matrix metalloproteinase-9 (MMP-9). It was developed as a potential therapeutic agent for inflammatory diseases and cancer, with clinical trials primarily focusing on ulcerative colitis and gastric/gastroesophageal junction adenocarcinoma. The antibody functions by allosterically inhibiting the enzymatic activity of MMP-9, aiming to reduce tissue degradation, modulate the tumor microenvironment, and decrease inflammation. Despite advancing to Phase III trials in combination with chemotherapy for gastric cancer, its development was discontinued after the trial did not meet its primary endpoint of improving overall survival.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.